Gynecomastia Diagnosis and Management

Diagnostic Evaluation

Most men with breast symptoms can be diagnosed based on clinical findings without imaging, according to the American College of Radiology 1, 2, 3
Gynecomastia presents as a soft, rubbery, or firm mobile mass directly under the nipple and is often painful, especially when present for less than 6 months, as noted by the American College of Radiology 4
Gynecomastia is bilateral in approximately 50% of patients, as reported by the American College of Radiology 2
Differentiate true gynecomastia from pseudogynecomastia (fatty tissue deposition rather than glandular tissue enlargement), especially in patients with elevated BMI, as recommended by the American College of Radiology 3

Initial Management Algorithm

Step 1: Determine if imaging is needed

For men with clinical findings consistent with gynecomastia or pseudogynecomastia, no imaging is routinely recommended, according to the American College of Radiology 5, 6
If the differentiation between benign disease and breast cancer cannot be made clinically, or if presentation is suspicious, proceed with imaging, as suggested by the American College of Radiology 4
For indeterminate breast masses:
- Men younger than 25: Ultrasound is the initial recommended imaging study, as recommended by the American College of Radiology 7
- Men 25 and older: Mammography or digital breast tomosynthesis is recommended, according to the American College of Radiology 7

Important Considerations

Breast cancer in males is rare (accounting for <1% of all breast cancers) but should be ruled out, especially in older men (median age 63 years), as noted by the American College of Radiology 4

Common Pitfalls to Avoid

Unnecessary imaging in clear cases of gynecomastia can lead to additional unnecessary benign biopsies, as warned by the American College of Radiology 2

Management of Male Breast Enlargement and Inflammation

Diagnostic Considerations

The American College of Radiology recommends that patients with unilateral breast enlargement since adolescence with inflammation be evaluated for gynecomastia, which is the most common cause of breast enlargement in males 8

Referral Algorithm

The American Urological Association recommends that men with elevated baseline estradiol measurements be referred to an endocrinologist to determine the underlying hormonal cause of the gynecomastia 9
An endocrinologist will assess for potential hormonal imbalances, including testosterone deficiency, elevated estradiol levels, abnormal luteinizing hormone (LH) levels, and hyperprolactinemia 9

Diagnostic Testing to Expect

The endocrinologist will likely order serum testosterone levels, serum estradiol levels, luteinizing hormone (LH) levels, and prolactin levels if testosterone is low with low/normal LH 9

Secondary Referrals (if needed)

For men 25 and older, the Journal of the American College of Radiology recommends mammography or digital breast tomosynthesis as the initial imaging study if imaging is deemed necessary after endocrine evaluation 8

Treatment of Gynecomastia Causing Nipple Pain

Initial Evaluation and Management

Patients with elevated baseline estradiol measurements should be referred to an endocrinologist, as guided by The Journal of Urology 10

Treatment Algorithm

Step 2: Observation for Physiologic Gynecomastia

Noncyclical breast pain tends to be of shorter duration than cyclical mastalgia, with spontaneous resolution occurring in up to 50% of patients, as reported by the Journal of the American College of Radiology 11

Step 3: Medical Therapy for Persistent, Painful Gynecomastia

Estrogen receptor modulators may be considered for testosterone deficient patients with low or low/normal LH levels, according to The Journal of Urology 10
Men with testosterone deficiency who develop gynecomastia/breast symptoms on testosterone treatment should undergo a period of monitoring as symptoms sometimes abate, as recommended by The Journal of Urology 10

Special Considerations

Men with gynecomastia who are interested in fertility should have a reproductive health evaluation performed prior to treatment, as advised by The Journal of Urology 10
Serum estradiol should be measured in testosterone deficient patients who present with breast symptoms or gynecomastia prior to starting testosterone therapy, as suggested by The Journal of Urology 10

Management of Gynecomastia

Treatment of Persistent Gynecomastia

To prevent painful gynecomastia in patients starting antiandrogen therapy, breast irradiation (8-15 Gy in 1-3 fractions) should be given 1-2 weeks before initiation, as recommended by the American Society of Clinical Oncology 12

Evaluation of Gynecomastia

Physical Examination Components

The American Urological Association recommends evaluating general body habitus and calculating body mass index (BMI) or measuring waist circumference to assess for signs of underlying systemic conditions 13
The American Urological Association suggests assessing virilization status by examining body hair patterns and amounts in androgen-dependent areas to evaluate for hypogonadism 13
A complete testicular examination should be performed to assess testicular size, consistency, and presence of masses, and to evaluate for the presence of varicocele 13
The American Urological Association recommends assessing prostate size and morphology to look for abnormalities that might indicate prostate pathology 13
Visual field changes (bitemporal hemianopsia) should be examined to suggest pituitary disorders, which may be associated with gynecomastia 13

Biopsy Approach for Suspicious Gynecomastia

Diagnostic Algorithm Before Biopsy

For men younger than 25 years with suspicious breast findings, ultrasound is recommended as the initial imaging study, followed by mammography or digital breast tomosynthesis (DBT) if suspicious features are found, as recommended by the American College of Radiology 14, 15
For men 25 years and older with suspicious breast findings, mammography or DBT is recommended as the initial imaging study, with ultrasound to follow if the mammogram is indeterminate or suspicious, according to the American College of Radiology 15
Mammography has high sensitivity (92-100%), specificity (90-96%), and negative predictive value (99-100%) for male breast evaluation, as reported by the American College of Radiology 15

Biopsy Technique Selection

Core needle biopsy is superior to fine-needle aspiration (FNA) in terms of sensitivity, specificity, and correct histological grading, as stated by the American College of Radiology 16
Image-guided core biopsy is the procedure of choice for most image-detected breast lesions requiring tissue diagnosis, according to the American College of Radiology 16
Ultrasound guidance is preferred for core needle biopsy due to patient comfort, real-time visualization of the needle, absence of ionizing radiation, and sampling accuracy, as recommended by the American College of Radiology 16

Guidance Method Selection

For lesions visible on ultrasound, ultrasound-guided core biopsy is preferred, as stated by the American College of Radiology 16, 17
For lesions only visible on mammography, stereotactic-guided core biopsy is recommended, according to the American College of Radiology 17, 18
For lesions only visible on DBT, DBT-guided core biopsy is recommended, as stated by the American College of Radiology 17, 18

Post-Biopsy Considerations

A post-biopsy marker clip should be placed to confirm tissue sampling of the target lesion and aid in correlation when biopsy was performed with a different imaging modality than initial detection, as recommended by the American College of Radiology 17, 18
Post-biopsy imaging should be performed to document marker placement, according to the American College of Radiology 17

Special Considerations

Male breast cancer is rare (median age 63 years) but should be ruled out in suspicious cases, as reported by the American College of Radiology 15
Imaging should precede biopsy as post-biopsy changes may confuse image interpretation, according to the American College of Radiology 17, 18

Evaluation and Management of Male Breast Symptoms

Imaging Recommendations

For men 25 years and older with an indeterminate mass, the American College of Radiology recommends bilateral diagnostic mammography or tomosynthesis as the initial exam, with a sensitivity of 92-100%, specificity of 90-96%, and negative predictive value of 99-100% 19, 20, 21
For men under 25 years, ultrasound is recommended as the initial exam, with mammography or tomosynthesis considered if ultrasound shows suspicious characteristics 21

Clinical Evaluation

The American College of Radiology suggests that imaging is indicated only if the differentiation between benign disease and breast cancer cannot be made clinically, or if the presentation is suspicious (unilateral mass, hard, fixed, or eccentric) 19, 20

Treatment of Breast Pain

No specific treatment guidelines are provided with associated citations, however, the article mentions that observation and over-the-counter pain medications may be considered for non-cyclic breast pain 19, 20

Important Considerations

The presence of a bloody nipple discharge is a sign that requires immediate imaging, as recommended by the American College of Radiology 22
A retracted skin or nipple is also a sign that requires immediate imaging, as recommended by the American College of Radiology 20

Role of Total Estrogen Level in Male Gynecomastia

Diagnostic Considerations

The American Urological Association recommends measuring serum estradiol in men presenting with gynecomastia, particularly in testosterone-deficient patients prior to starting testosterone therapy, and men with elevated baseline estradiol measurements should be referred to an endocrinologist 23, 24, 25
Measure serum estradiol in all testosterone-deficient patients who present with breast symptoms or gynecomastia before commencing testosterone therapy 23, 24, 25

Management Based on Estradiol Findings

Mandatory endocrinology referral for all patients with elevated baseline estradiol 23, 24, 25
Consider selective estrogen receptor modulator therapy in testosterone-deficient patients with low or low-normal LH levels 23, 24, 25

Special Populations

Men interested in fertility should have reproductive health evaluation (testicular exam, FSH measurement) before treatment 23, 24, 25
Testosterone-deficient patients with low or low-normal LH are candidates for selective estrogen receptor modulator use, particularly those wishing to preserve fertility 23, 24, 25

Evaluation and Management of Unilateral Breast Swelling in Adolescent Males

Initial Imaging Recommendations

The American College of Radiology recommends that no imaging is routinely recommended for boys with clinical findings consistent with gynecomastia, as this leads to additional unnecessary benign biopsies without improving outcomes 26, 27
For boys under 25 years of age with indeterminate or suspicious clinical examination findings, ultrasound is the initial imaging modality of choice due to the extremely low incidence of breast cancer in young males 26, 27

Diagnostic Approach

If ultrasound shows suspicious or indeterminate features, the American College of Radiology suggests proceeding to mammography or digital breast tomosynthesis before making a biopsy recommendation, as gynecomastia and benign lesions can appear suspicious on ultrasound but are typically diagnosed as benign on mammography 26, 27

Hormonal Evaluation and Diabetes‑Related Considerations in Gynecomastia Management

Laboratory Assessment

Diabetes Impact on Hormonal Profile

Cardiovascular Considerations of Testosterone Therapy

All statements are derived from peer‑reviewed evidence cited above.

Prophylaxis and Hormonal Causes of Drug‑Induced Gynecomastia

Radiation Prophylaxis

Pre‑emptive breast irradiation (8–15 Gy delivered in 1–3 fractions, administered 1–2 weeks before starting anti‑androgen therapy) markedly reduces the incidence of painful gynecomastia in men receiving anti‑androgen agents for prostate cancer or other androgen‑dependent conditions 30.

Hormonal Therapies that Promote Gynecomastia

GnRH agonists such as leuprolide and goserelin suppress testicular testosterone production, creating an estrogen‑dominant hormonal milieu that can precipitate gynecomastia in male patients undergoing hormonal suppression for prostate cancer or endocrine disorders 30.
Exogenous estrogens and estrogen‑like compounds—including diethylstilbestrol (DES), digoxin, and phytoestrogens—directly increase estrogenic activity and are recognized pharmacologic triggers of gynecomastia in men 30.

Management of Gynecomastia in Men Receiving Testosterone Replacement Therapy

Initial Evaluation

Measure serum estradiol in every testosterone‑deficient man who presents with breast symptoms or gynecomastia before altering the testosterone regimen; if estradiol is elevated, refer to endocrinology for a full hormonal work‑up. 31
For men who develop gynecomastia or breast tenderness while on testosterone, adopt a short‑term observation period guided by clinical judgment, because breast symptoms may resolve spontaneously. 31

Understanding Hormonal Dynamics

Although total testosterone rise on therapy often leads to modest increases in estradiol, clinically significant (symptomatic) gynecomastia remains uncommon. 31
Injectable testosterone formulations tend to cause larger increases in hemoglobin/hematocrit and produce more fluctuating estradiol levels compared with transdermal preparations. 31

Therapeutic Decision‑Making

If estradiol is normal or only mildly elevated, continue the current testosterone dose and monitor closely; up to 50 % of patients experience spontaneous resolution of breast symptoms. 31
When estradiol is markedly elevated and symptoms persist despite observation, consider reducing the testosterone dose. 31
Switching from an injectable to a transdermal testosterone product may lower peak testosterone concentrations and reduce subsequent aromatization to estradiol. 31

Safety Monitoring During TRT

Check hematocrit at every clinic visit; withhold testosterone when hematocrit exceeds 54 % and consider therapeutic phlebotomy for patients at high risk of thrombosis. 31
Monitor prostate‑specific antigen (PSA) in men older than 40 years; refer for urologic evaluation if PSA rises >1.0 ng/mL within the first six months of therapy or >0.4 ng/mL per year thereafter. 31
Perform a digital rectal examination at each visit to screen for prostate abnormalities. 32

Clinical Pitfalls to Avoid

Do not discontinue testosterone immediately without first measuring estradiol and allowing an observation period, as many breast symptoms improve without therapy change. 31